Hansoh Pharmaceutical Group
$34.14Change from previous close: −3.29%Absolute change: −$1.16
At a glance
- Revenue growth
- +22.57%
- 2025 vs 2024
- Net income growth
- +27.07%
- 2025 vs 2024
- Net margin
- 37.0%
- 2024: 35.7%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 6,738 | 3,862 | 3,116 | 2,741 | 2,577 |
| Depreciation and amortization | 391 | 401 | 366 | 345 | 278 |
| Capital expenditure | -356 | -222 | -220 | -273 | -460 |
| Investing cash flow | -7,155 | -1,392 | 1,074 | -5,935 | -2,259 |
| Financing cash flow | 1,554 | -6,066 | -754 | -818 | 3,417 |
| Dividends paid | -2,012 | -1,858 | -652 | -712 | -381 |
| Share repurchases | — | -33.7 | -115 | -76.6 | -58.0 |
| Debt issued | 0.0 | 500 | 900 | 0.0 | 3,877 |
| Debt repaid | -22.4 | -4,704 | -919 | -42.5 | -12.3 |
| Effect of exchange rates | -51.6 | -62.4 | -122 | -40.6 | -79.3 |
| Net change in cash | 1,086 | -3,658 | 3,314 | -4,053 | 3,655 |
| Free cash flow | 6,382 | 3,640 | 2,897 | 2,468 | 2,117 |
| Levered free cash flow | 5,162 | 2,401 | 2,069 | 1,453 | 1,256 |